covid
Buscar en
Gaceta Mexicana de Oncología
Toda la web
Inicio Gaceta Mexicana de Oncología Impacto pronóstico de la respuesta patológica completa y del estado ganglionar...
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

ARTÍCULO ORIGINAL
Impacto pronóstico de la respuesta patológica completa y del estado ganglionar en pacientes con cáncer de mama avanzado tratadas con dosis alta de epirrubicina neoadyuvante
Prognostic impact of complete pathological response and lymph node status in patients with advanced breast cancer treated with high-dose neoadjuvant epirubicin
Nicolás Ramírez-Torresa,
Autor para correspondencia
nicolasestudio14@yahoo.com.mx

Autor para correspondencia. Calzada Vallejo Esq. con Antonio Valeriano S/N, Col. La Raza, Delegación Azcapotzalco, CP 02990, Ciudad de México, México. Tel.: +(525) 55 5724 5900 ext. 23 615.
, Ancizar Pérez-Puentesb, Rodolfo Rivas-Ruizc, Juan O. Talaverac, Horacio Astudillo-de la Vegad
a Servicio de Ginecología Oncológica, UMAE del Hospital de Ginecología y Obstetricia n.° 3, Centro Médico Nacional (CMN) La Raza, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México
b Servicio de Oncología Médica, UMAE del Hospital de Ginecología y Obstetricia n.° 3, CMN La Raza, IMSS, Ciudad de México, México
c Centro de Adiestramiento en Investigación Clínica, Coordinación de Investigación en Salud, CMN SXXI, IMSS, Ciudad de México, México
d Laboratorio de Investigación Traslacional y Terapia Celular, Centro Médico Nacional SXXI, IMSS, Ciudad de México, México
Leído
6786
Veces
se ha leído el artículo
754
Total PDF
6032
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S1665920116300281"
  "issn" => "16659201"
  "doi" => "10.1016/j.gamo.2016.05.005"
  "estado" => "S300"
  "fechaPublicacion" => "2016-05-01"
  "aid" => "96"
  "copyright" => "Sociedad Mexicana de Oncología"
  "copyrightAnyo" => "2016"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "GAMO. 2016;15:128-37"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1816
    "formatos" => array:3 [
      "EPUB" => 60
      "HTML" => 1446
      "PDF" => 310
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1665920116300232"
    "issn" => "16659201"
    "doi" => "10.1016/j.gamo.2016.04.002"
    "estado" => "S300"
    "fechaPublicacion" => "2016-05-01"
    "aid" => "91"
    "copyright" => "Sociedad Mexicana de Oncología"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "GAMO. 2016;15:138-44"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 989
      "formatos" => array:3 [
        "EPUB" => 40
        "HTML" => 638
        "PDF" => 311
      ]
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">ART&#205;CULO ORIGINAL</span>"
      "titulo" => "Gefitinib concurrente con quimiorradiaci&#243;n en el c&#225;ncer de cabeza y cuello localmente avanzado"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "138"
          "paginaFinal" => "144"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Gefitinib with concurrent chemoradiation in locally advanced head and neck cancer"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1208
              "Ancho" => 2339
              "Tamanyo" => 171228
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Supervivencia libre de progresi&#243;n y global&#46; Estimada con el m&#233;todo de Kaplan-Meier&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Surendra Kumar Saini, Shely Srivastava, Awadhesh Kumar Dixit"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Surendra Kumar"
              "apellidos" => "Saini"
            ]
            1 => array:2 [
              "nombre" => "Shely"
              "apellidos" => "Srivastava"
            ]
            2 => array:2 [
              "nombre" => "Awadhesh Kumar"
              "apellidos" => "Dixit"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665920116300232?idApp=UINPBA00004N"
    "url" => "/16659201/0000001500000003/v1_201607090026/S1665920116300232/v1_201607090026/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S166592011630027X"
    "issn" => "16659201"
    "doi" => "10.1016/j.gamo.2016.05.004"
    "estado" => "S300"
    "fechaPublicacion" => "2016-05-01"
    "aid" => "95"
    "copyright" => "Sociedad Mexicana de Oncolog&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "GAMO. 2016;15:121-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1603
      "formatos" => array:3 [
        "EPUB" => 57
        "HTML" => 909
        "PDF" => 637
      ]
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Art&#237;culo original</span>"
      "titulo" => "Validaci&#243;n del test Meaning in Life Scale &#40;MILS&#41; modificado para evaluar la dimensi&#243;n espiritual en poblaci&#243;n chilena y latinoamericana con c&#225;ncer en cuidados paliativos"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "121"
          "paginaFinal" => "127"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Validation of Meaning in Life Scale modified to evaluate the spiritual dimension in a Chilean and Latin-American cancer population on palliative care"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1600
              "Ancho" => 1659
              "Tamanyo" => 115288
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Valoraci&#243;n de la consistencia interna y grado de concordancia entre 2 observadores del test de MILS modificado&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Guido Schiappacasse Cocio, Patricio Gonz&#225;lez Soto"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Guido"
              "apellidos" => "Schiappacasse Cocio"
            ]
            1 => array:2 [
              "nombre" => "Patricio"
              "apellidos" => "Gonz&#225;lez Soto"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S166592011630027X?idApp=UINPBA00004N"
    "url" => "/16659201/0000001500000003/v1_201607090026/S166592011630027X/v1_201607090026/es/main.assets"
  ]
  "es" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">ART&#205;CULO ORIGINAL</span>"
    "titulo" => "Impacto pron&#243;stico de la respuesta patol&#243;gica completa y del estado ganglionar en pacientes con c&#225;ncer de mama avanzado tratadas con dosis alta de epirrubicina neoadyuvante"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "128"
        "paginaFinal" => "137"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Nicol&#225;s Ram&#237;rez-Torres, Ancizar P&#233;rez-Puentes, Rodolfo Rivas-Ruiz, Juan O&#46; Talavera, Horacio Astudillo-de la Vega"
        "autores" => array:5 [
          0 => array:4 [
            "nombre" => "Nicol&#225;s"
            "apellidos" => "Ram&#237;rez-Torres"
            "email" => array:1 [
              0 => "nicolasestudio14&#64;yahoo&#46;com&#46;mx"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Ancizar"
            "apellidos" => "P&#233;rez-Puentes"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Rodolfo"
            "apellidos" => "Rivas-Ruiz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Juan O&#46;"
            "apellidos" => "Talavera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Horacio"
            "apellidos" => "Astudillo-de la Vega"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Servicio de Ginecolog&#237;a Oncol&#243;gica&#44; UMAE del Hospital de Ginecolog&#237;a y Obstetricia n&#46;&#176; 3&#44; Centro M&#233;dico Nacional &#40;CMN&#41; La Raza&#44; Instituto Mexicano del Seguro Social &#40;IMSS&#41;&#44; Ciudad de M&#233;xico&#44; M&#233;xico"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Oncolog&#237;a M&#233;dica&#44; UMAE del Hospital de Ginecolog&#237;a y Obstetricia n&#46;&#176; 3&#44; CMN La Raza&#44; IMSS&#44; Ciudad de M&#233;xico&#44; M&#233;xico"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Centro de Adiestramiento en Investigaci&#243;n Cl&#237;nica&#44; Coordinaci&#243;n de Investigaci&#243;n en Salud&#44; CMN SXXI&#44; IMSS&#44; Ciudad de M&#233;xico&#44; M&#233;xico"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Laboratorio de Investigaci&#243;n Traslacional y Terapia Celular&#44; Centro M&#233;dico Nacional SXXI&#44; IMSS&#44; Ciudad de M&#233;xico&#44; M&#233;xico"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46; Calzada Vallejo Esq&#46; con Antonio Valeriano S&#47;N&#44; Col&#46; La Raza&#44; Delegaci&#243;n Azcapotzalco&#44; CP 02990&#44; Ciudad de M&#233;xico&#44; M&#233;xico&#46; Tel&#46;&#58; &#43;&#40;525&#41; 55 5724 5900 ext&#46; 23 615&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Prognostic impact of complete pathological response and lymph node status in patients with advanced breast cancer treated with high-dose neoadjuvant epirubicin"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figura 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 3042
            "Ancho" => 1358
            "Tamanyo" => 204246
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Diferencias en las curvas Kaplan-Meier de acuerdo a la respuesta patol&#243;gica de las pacientes con cancer de mama avanzado&#46; Las pacientes con RPc tuvieron un ligero incremento no significativo en la A&#41; supervivencia libre de enfermedad y B&#41; supervivencia global&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">La eficacia de las antraciclinas &#40;doxorrubicina y epirubicina&#41; han sido probadas como tratamiento de primera l&#237;nea en el c&#225;ncer de mama localmente avanzado &#40;CMLA&#41; y en el c&#225;ncer de mama operable<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">1&#8211;3</span></a>&#46; Hoy en d&#237;a&#44; la quimioterapia neoadyuvante &#40;QN&#41; es parte del manejo multidisciplinario seguido de cirug&#237;a y radioterapia&#46; La QN ha demostrado varios beneficios al permitir la erradicaci&#243;n de micromet&#225;stasis&#44; la reducci&#243;n de volumen del tumor primario lo que permite la resecci&#243;n quir&#250;rgica total o parcial en algunas pacientes<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">4&#8211;6</span></a> y su eficacia ha demostrado un incremento m&#225;s prolongado en la supervivencia libre de enfermedad<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">2&#44;3</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El reporte de la respuesta cl&#237;nica es com&#250;n y la subetapificaci&#243;n cl&#237;nica despu&#233;s de la QN no siempre proporciona evidencia definitiva de que el tama&#241;o del tumor se ha reducido por completo<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">2&#44;3</span></a>&#46; La expresi&#243;n de los biomarcadores del tumor deben ser incorporados a las caracter&#237;sticas cl&#237;nicas para establecer un mejor tratamiento<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">7&#8211;10</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Los resultados de varios ensayos han considerado como factores predictivos o de pron&#243;stico de la QN a los ganglios linf&#225;ticos metast&#225;sicos<a class="elsevierStyleCrossRefs" href="#bib0245"><span class="elsevierStyleSup">5&#44;6&#44;11&#44;12</span></a>&#44; tama&#241;o del tumor<a class="elsevierStyleCrossRefs" href="#bib0245"><span class="elsevierStyleSup">5&#44;6&#44;11</span></a>&#44; el estado del receptor de estr&#243;geno &#40;RE&#41;<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">6&#44;11</span></a>&#44; y la expresi&#243;n de varios marcadores biol&#243;gicos &#40;p53<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">7&#8211;9&#44;13</span></a>&#44; Ki-67<a class="elsevierStyleCrossRefs" href="#bib0290"><span class="elsevierStyleSup">14&#44;15</span></a>&#44; c-erb2<a class="elsevierStyleCrossRefs" href="#bib0265"><span class="elsevierStyleSup">9&#44;16</span></a>&#41;&#46; Los hallazgos a menudo son variables&#44; contradictorios y no concluyentes&#44; se puede atribuir a varios factores como al dise&#241;o de los ensayos&#44; la poblaci&#243;n heterog&#233;nea de pacientes&#44; y a los diferentes reg&#237;menes quimioterap&#233;uticos<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">6&#8211;12</span></a>&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">La epirrubicina neoadyuvante ha demostrado su eficacia al incrementar la dosis de 100 a 150<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> para obtener mejores resultados<a class="elsevierStyleCrossRefs" href="#bib0305"><span class="elsevierStyleSup">17&#8211;19</span></a>&#46; Todas estas observaciones pueden justificar un incremento escalonado de dosis altas de epirrubicina durante los primeros meses de la QN&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">El prop&#243;sito de este estudio fue evaluar el impacto pron&#243;stico de las pacientes con respuesta patol&#243;gica completa &#40;RPc&#41; y con afecci&#243;n ganglionar persistente posterior al uso de epirrubicina neoadyuvante con dosis alta &#40;100<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#41; ya sea de 4 ciclos o 6 ciclos&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Pacientes y m&#233;todos</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Selecci&#243;n de las pacientes</span><p id="par0030" class="elsevierStylePara elsevierViewall">Este estudio retrospectivo&#44; observacional&#44; longitudinal y comparativo registr&#243; un total de 120 pacientes consecutivas de febrero de 2003 a diciembre de 2010&#46; Las pacientes fueron tratadas en la Unidad M&#233;dica de Alta Especialidad del Hospital de Ginecolog&#237;a y Obstetricia n&#46;&#176;&#46; 3&#44; Centro M&#233;dico Nacional La Raza&#44; Instituto Mexicano del Seguro Social&#44; al t&#233;rmino de la QN se program&#243; cirug&#237;a&#44; radioterapia y quimioterapia adyuvante para las pacientes con tumor residual&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Se eligieron pacientes con diagn&#243;stico cl&#237;nico de c&#225;ncer de mama en estadio IIIA&#44; IIIB y IIIC sin evidencia de met&#225;stasis a distancia de acuerdo a las normas del American Joint Committee on Cancer &#40;AJCC 2002&#41;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">20</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Los criterios de inclusi&#243;n&#44; de exclusi&#243;n&#44; metodolog&#237;a de estudios de laboratorio y de gabinete adem&#225;s del tipo de cirug&#237;a&#44; radioterapia y hormonoterapia se describen en estudio previo<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">21</span></a>&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Quimioterapia neoadyuvante</span><p id="par0045" class="elsevierStylePara elsevierViewall">Las pacientes fueron tratadas con 5-fluorouracilo 500<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#44; epirrubicina 100<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> y ciclofosfamida 600<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> &#40;FE<span class="elsevierStyleInf">100</span>C&#41; el d&#237;a 1&#44; cada 21-28 d&#237;as sin apoyo de factores de crecimiento hematopoy&#233;tico&#44; los f&#225;rmacos fueron aplicados por v&#237;a intravenosa&#46; La primera cohorte &#40;n &#61; 60&#41; recibi&#243; 4 ciclos &#40;4 FE<span class="elsevierStyleInf">100</span>C&#41; que inici&#243; de febrero de 2003 hasta diciembre de 2004 y a partir de enero de 2005 en adelante&#44; la segunda cohorte &#40;n &#61; 60&#41; recibi&#243; 6 ciclos &#40;6 FE<span class="elsevierStyleInf">100</span>C&#41; de acuerdo con la pr&#225;ctica habitual de la &#233;poca&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Criterios de respuesta</span><p id="par0050" class="elsevierStylePara elsevierViewall">La respuesta cl&#237;nica de acuerdo a la OMS<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">22</span></a> y la respuesta patol&#243;gica de acuerdo al criterio de Chevallier<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">23</span></a> se describen en estudio previo<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">21</span></a>&#46; Los resultados parciales de estos par&#225;metros fueron tomados en cuenta para este estudio para establecer diferencias en la supervivencia en ambas cohortes&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Seguimiento</span><p id="par0055" class="elsevierStylePara elsevierViewall">Al t&#233;rmino de la quimioterapia adyuvante&#44; las pacientes fueron evaluadas cada 3 meses durante los primeros 2 a&#241;os de seguimiento con examen f&#237;sico y pruebas de funci&#243;n hep&#225;tica&#44; estos estudios se realizaron cada 6 meses durante los siguientes 3 a&#241;os&#46; Los siguientes estudios fueron realizados cada 12 meses durante 5 a&#241;os&#58; radiograf&#237;a de t&#243;rax&#44; radiograf&#237;a &#243;sea completa&#44; ultrasonido abdominal y una mastograf&#237;a&#46; Si la paciente mostr&#243; pruebas elevadas de la funci&#243;n hep&#225;tica o un ultrasonido abdominal anormal se realiz&#243; una tomograf&#237;a abdominal computada&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">M&#233;todo estad&#237;stico</span><p id="par0060" class="elsevierStylePara elsevierViewall">Los principales criterios de valoraci&#243;n fueron la tasa de efectividad &#40;RPc&#44; sin evidencia de c&#233;lulas tumorales en la mama y en los ganglios linf&#225;ticos&#41;&#46; Los criterios secundarios de valoraci&#243;n fueron la tasa de respuesta objetiva &#40;RO&#58; RC &#43; RP&#41;&#44; la supervivencia libre de enfermedad &#40;SLE&#41; y la supervivencia global &#40;SG&#41;&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">Las variables categ&#243;ricas basales muestran las frecuencias de la poblaci&#243;n de estudio&#46; La prueba de chi cuadrado de Pearson o prueba exacta de Fisher fueron usadas seg&#250;n tendencia para comparar variables categ&#243;ricas y las tasas de respuesta cl&#237;nica y patol&#243;gica de ambas cohortes&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">La SLE se midi&#243; a partir de la fecha de cirug&#237;a hasta la primera fecha de reca&#237;da de la enfermedad&#44; fallecimiento o &#250;ltimo seguimiento&#46; La SG se midi&#243; a partir de la fecha del diagn&#243;stico histol&#243;gico hasta la fecha del fallecimiento o &#250;ltimo seguimiento&#46; El tiempo fue medido en meses&#46; Los siguientes eventos fueron considerados en la SLE&#58; recidiva &#40;locorregional&#44; a distancia o ambos&#41; y muerte por cualquier causa&#46; Las pacientes vivas y abandonos fueron censurados&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">Se utiliz&#243; el modelo de regresi&#243;n log&#237;stica para determinar la probabilidad de lograr una RPc y los factores predictivos incluidos en el an&#225;lisis fueron&#58; edad&#44; estadio cl&#237;nico&#44; estado menop&#225;usico&#44; RE&#44; RPg&#44; HER2&#44; grado histol&#243;gico y n&#250;mero de ciclos administrados&#46; Los resultados fueron expresados como raz&#243;n de momios &#40;por sus siglas en ingl&#233;s OR&#41; con sus intervalos de confianza del 95&#37; &#40;IC 95&#37;&#41; y valores de <span class="elsevierStyleItalic">p</span> correspondientes&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Las curvas de supervivencia se estimaron mediante el m&#233;todo de Kaplan-Meier<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">24</span></a> y se emple&#243; la prueba de rangos logar&#237;tmicos para comparar diferencias en ambas cohortes&#59; el modelo de riesgo proporcional de Cox<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">25</span></a> se llev&#243; a cabo para evaluar la influencia relativa de los factores predictivos y la prueba de rangos logar&#237;tmicos se realiz&#243; para comparar grupos&#46; En ambos m&#233;todos se estim&#243; la raz&#243;n de riesgos &#40;por sus siglas en ingl&#233;s HR&#41; con IC 95&#37; y valores de <span class="elsevierStyleItalic">p</span> correspondientes&#46; En el modelo de Cox las siguientes covariables fueron predefinidas&#58; edad &#40;&#60; 50 a&#241;os vs&#46; &#62; 50 a&#241;os&#41;&#44; estadio cl&#237;nico &#40;IIIB-C vs&#46; IIIA&#41;&#44; RE &#40;negativo vs&#46; positivo&#41;&#44; HER2 &#40;positivo vs&#46; negativo&#44; RPc &#40;no vs&#46; s&#237;&#41;&#44; n&#250;mero de ganglios positivos posquimioterapia &#40;&#62; 4 vs&#46; 1-3 vs&#46; 0&#41; y n&#250;mero de ciclos &#40;4 vs&#46; 6&#41;&#46; Adem&#225;s&#44; se evalu&#243; el impacto del estado del RE de acuerdo a la RPc en la SLE&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Todos los valores fueron de dos colas con un nivel de significaci&#243;n de 5&#37; y un poder de 80&#37;&#46; Los an&#225;lisis estad&#237;sticos fueron realizados en un software estad&#237;stico denominado SPSS versi&#243;n 15 &#40;SPSS Inc&#46;&#44; Chicago&#44; IL&#41;&#46;</p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Resultados</span><p id="par0090" class="elsevierStylePara elsevierViewall">Las caracter&#237;sticas clinicopatol&#243;gicas de ambas cohortes se comportaron de manera similar como se muestra en la <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#46; Para el grupo entero&#44; la mediana de edad fue de 51 a&#241;os &#40;l&#237;mites&#58; 28 a 74&#41;&#46; De acuerdo con la enfermedad avanzada&#44; 76 pacientes &#40;63&#46;3&#37;&#41; correspondieron a EC IIIA&#44; 41 &#40;34&#46;1&#37;&#41; a EC IIIB y solo 3 &#40;2&#46;5&#37;&#41; a EC IIIC&#46; El promedio del tama&#241;o del tumor fue de 7&#46;1 &#177; 2&#46;3<span class="elsevierStyleHsp" style=""></span>cm debido al diagn&#243;stico del c&#225;ncer en etapa avanzada&#46; La mayor&#237;a de los tumores independientemente del tama&#241;o del tumor correspondieron a RE positivo &#40;66&#46;6&#37;&#41; y HER2 negativo &#40;73&#46;3&#37;&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Respuesta cl&#237;nica</span><p id="par0095" class="elsevierStylePara elsevierViewall">La <a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a> muestra un incremento significativo en la tasa de RO a favor de la cohorte 6 FE<span class="elsevierStyleInf">100</span>C en comparaci&#243;n con la cohorte 4 FE<span class="elsevierStyleInf">100</span>C &#40;85 vs&#46; 65&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;011&#41;&#44; esto incluye la respuesta cl&#237;nica completa &#40;RCc&#41; del 33&#46;3&#37; &#40;IC 95&#37;&#44; 21&#46;2 a 45&#46;5&#41; con 6 FE<span class="elsevierStyleInf">100</span>C frente al 8&#46;3&#37; &#40;IC 95&#37;&#44; 1&#46;2 a 15&#46;5&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;005&#41; con 4 FE<span class="elsevierStyleInf">100</span>C&#46; Para el grupo entero&#44; se observ&#243; por evaluaci&#243;n cl&#237;nica una reducci&#243;n del tumor &#8805; 50&#37; posquimioterapia en 90 casos &#40;75&#37;&#41;&#46; De este grupo se obtuv&#243; una RCc en 26 pacientes &#40;28&#46;8&#37;&#41; con tumores T2-3 y en solo 3 casos &#40;3&#46;3&#37;&#41; con tumores T4&#46; Ninguna paciente tuvo progresi&#243;n de la enfermedad durante el tratamiento previo a la cirug&#237;a&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Respuesta patol&#243;gica</span><p id="par0100" class="elsevierStylePara elsevierViewall">Aunque los datos mostraron un ligero incremento en la tasa de RPc a favor de 6 FE<span class="elsevierStyleInf">100</span>C en comparaci&#243;n con 4 FE<span class="elsevierStyleInf">100</span>C &#40;16&#46;7 vs&#46; 10&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;283&#41;&#44; en la interacci&#243;n del tratamiento la diferencia no alcanz&#243; la significaci&#243;n estad&#237;stica &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">La ocurrencia de ganglios linf&#225;ticos axilares negativos posquimioterapia fue similar para 4 FE<span class="elsevierStyleInf">100</span>C y 6 FE<span class="elsevierStyleInf">100</span>C &#40;33&#46;3 y 35&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;847&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0110" class="elsevierStylePara elsevierViewall">Del grupo entero&#44; 17 de las 37 pacientes &#40;45&#46;9&#37;&#41; con ganglio cl&#237;nico N1 tuvieron ganglios patol&#243;gicos positivos &#40;pN&#43;&#41;&#46; Con enfermedad N2&#44; 58 de 79 pacientes &#40;73&#46;4&#37;&#41; tuvieron pN&#43;&#44; y solo 6 pacientes &#40;5&#37;&#41; tuvieron m&#225;s de 10 pN&#43;&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">El grupo de pacientes con RPc tuvieron menor tasa de recidivas a distancia en comparaci&#243;n con aquellas que ten&#237;an una respuesta tumoral incompleta &#40;6&#46;2 vs&#46; 24&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;107&#41;&#44; aunque la diferencia no alcanz&#243; la significaci&#243;n estad&#237;stica&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Las pacientes del grupo con respuesta tumoral primaria incompleta ten&#237;an m&#225;s probabilidad de presentar recidiva a distancia en los primeros 24 meses despu&#233;s de cirug&#237;a en comparaci&#243;n con las pacientes que tuvieron recidiva a distancia despu&#233;s de 24 meses &#40;57&#46;6&#37; &#91;n &#61; 15&#93; v 42&#46;3&#37; &#91;n &#61; 11&#93;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;530&#41;&#44; independientemente del n&#250;mero de ciclos&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">La aparici&#243;n de las recidivas de acuerdo con la condici&#243;n del tumor con RE&#44; los datos mostraron una mayor ocurrencia de recidiva a distancia en el grupo de pacientes con tumores RE positivo en 74&#37; &#40;n &#61; 20&#41; y estas ocurrieron en los primeros 24 meses en el 50&#37; &#40;n &#61; 10&#41;&#44; independientemente del tama&#241;o del tumor&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Predicci&#243;n de la RPc</span><p id="par0130" class="elsevierStylePara elsevierViewall">En el an&#225;lisis univariado y multivariado del modelo de regresi&#243;n log&#237;stica solo un factor tuvo mayor probabilidad de lograr una RPc&#44; el estadio cl&#237;nico con OR de 11 &#40;<span class="elsevierStyleItalic">p</span> &#61; 0&#46;023&#41; y OR de 11&#46;6 &#40;<span class="elsevierStyleItalic">p</span> &#61; 0&#46;020&#41;&#44; respectivamente&#46; En cambio&#44; el an&#225;lisis multivariado de la regresi&#243;n log&#237;stica no mostr&#243; diferencias con respecto al RE positivo &#40;OR&#44; 1&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;902&#41; y 6 ciclos administrados &#40;OR&#44; 2&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;217&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">An&#225;lisis univariado</span><p id="par0135" class="elsevierStylePara elsevierViewall">La <a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a> muestra la supervivencia de acuerdo a los factores pron&#243;sticos posquimioterapia&#46; El an&#225;lisis univariado revel&#243; que la etapa cl&#237;nica y n&#250;mero de pN&#43; fueron los factores independientes de la SLE y de la SG&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0140" class="elsevierStylePara elsevierViewall">Los tumores etapa IIIA en comparacion con tumores etapa IIIB-C fue un factor significativo para la SLE &#40;82 vs&#46; 61&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;042&#41; y para la SG &#40;80 vs&#46; 58&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;049&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a> y <a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0145" class="elsevierStylePara elsevierViewall">El n&#250;mero de pN&#43; tambi&#233;n fue un factor pron&#243;stico independiente&#44; las pacientes con pN0 y con menor n&#250;mero de pN&#43; &#40;1-3&#41; comparado con aquellas que ten&#237;an m&#225;s de 4 pN&#43; tuvieron una mejor SLE &#40;97&#44; 63&#44; 59&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;000&#41; y una SG &#40;96&#44; 61&#44; 57&#37;&#44; respectivamente&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;000&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a> y <a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>&#41;&#46; De las 79 pacientes con pN&#43; posquimioterapia&#44; 25 &#40;31&#46;6&#37;&#41; desarrollaron met&#225;stasis a distancia y del grupo con pN0 solo un caso tuvo una recidiva sist&#233;mica &#40;6&#46;2&#37;&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0150" class="elsevierStylePara elsevierViewall">Las pacientes con una RPc &#40;92&#37;&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;061&#41; y aquellas que recibieron un n&#250;mero mayor de ciclos administrados &#40;76&#37;&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;210&#41; tuvieron un impacto favorable en la SG&#44; aunque la diferencia no alcanz&#243; la significaci&#243;n estad&#237;stica como lo muestra la <a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a>&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">An&#225;lisis multivariado</span><p id="par0155" class="elsevierStylePara elsevierViewall">Los factores predictivos fueron previamente predefinidos&#46; De los cuales&#44; solo un factor parece ser independiente para la SLE y SG&#44; el estado ganglionar&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">El an&#225;lisis multivariado de Cox afirm&#243; que el n&#250;mero de pN&#43; es un factor pron&#243;stico independiente de la SG&#44; particularmente el subgrupo de 4 pN&#43; o m&#225;s tuvo el peor pron&#243;stico con HR de 19&#46;3 &#40;IC 95&#37;&#44; 2&#46;5-147&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;004&#41;&#46; En cambio&#44; no hubo diferencia significativa para el mayor n&#250;mero de ciclos administrados &#40;HR&#44; 1&#46;4&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;331&#41; y para la RPc &#40;HR&#44; 4&#46;1&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;170&#41; en la SG &#40;<a class="elsevierStyleCrossRef" href="#tbl0030">tabla 6</a> y <a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0165" class="elsevierStylePara elsevierViewall">Para el grupo entero&#44; durante el seguimiento con una mediana de 53 meses &#40;l&#237;mites&#44; 12- 85 meses&#41; del grupo RPc&#44; solo un caso present&#243; recidiva a distancia&#46; En cambio&#44; el grupo de pacientes con tumor residual presentaron recidiva a distancia en 15 pacientes de la cohorte 4 FE<span class="elsevierStyleInf">100</span>C y en 11 pacientes de la cohorte 6 FE<span class="elsevierStyleInf">100</span>C&#46; Adem&#225;s&#44; en la cohorte 4 FE<span class="elsevierStyleInf">100</span>C hubo una recidiva local asociada con enfermedad sist&#233;mica&#44; y una muerte debido a complicaciones por insuficiencia renal avanzada sin enfermedad neopl&#225;sica&#46; En ambas cohortes&#44; todas las pacientes con tumor residual que tuvieron una recidiva a distancia posterior a la QN han muerto&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">La mediana de seguimiento de la SLE fue de 42 meses &#40;l&#237;mites&#44; 7 a 95&#41; para 4 FE<span class="elsevierStyleInf">100</span>C y de 46 meses &#40;l&#237;mites&#44; 4 a 69&#41; para 6 FE<span class="elsevierStyleInf">100</span>C&#46; La mediana de seguimiento de la SG fue de 49 meses &#40;l&#237;mites&#44; 14 a 85&#41; para 4 FE<span class="elsevierStyleInf">100</span>C y de 56 meses &#40;l&#237;mites&#44; 12 a 75&#41; para 6 FE<span class="elsevierStyleInf">100</span>C&#46; La ventaja de supervivencia total observada en las pacientes tratadas con 4 FE<span class="elsevierStyleInf">100</span>C se relaciona con el periodo inicial de selecci&#243;n de las pacientes&#46;</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Discusi&#243;n</span><p id="par0175" class="elsevierStylePara elsevierViewall">Nuestro estudio revel&#243; un ligero incremento de la tasa de RPc de las pacientes que recibieron 6 ciclos de epirrubicina en esta poblaci&#243;n de estudio&#46; Sin embargo&#44; el CMLA se asocia con un mal pron&#243;stico&#44; y es dif&#237;cil predecir el curso cl&#237;nico incluso a&#250;n cuando los tumores tienen una RPc&#44; debido a que las respuestas tienen diversos resultados a la quimioterapia&#46; La mayor&#237;a de los casos son tratados satisfactoriamente con un tratamiento multidisciplinario&#44; pero la tasa de mortalidad a&#250;n no ha disminuido para este grupo de pacientes<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">2&#44;3&#44;6&#44;7&#44;26</span></a>&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Actualmente&#44; la RPc se considera como el factor pron&#243;stico m&#225;s poderoso y se asocia con un incremento de la SLE a largo plazo&#46; Un gran n&#250;mero de estudios han mostrado que las pacientes que han obtenido una RPc tienen una mejor SLE a 5 a&#241;os &#40;aproximadamente del 90&#37;&#41; en comparaci&#243;n con aquellas pacientes con tumor residual &#40;menor del 60&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">2&#44;3&#44;8</span></a>&#46; La tasa de RPc tambi&#233;n incluye el estado de los ganglios linf&#225;ticos patol&#243;gicos<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">6&#8211;12&#44;27&#44;28</span></a>&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">Las tasas de recidiva local y sist&#233;mica var&#237;an de acuerdo con diferentes series&#44; pero en general&#44; las recidivas a distancia son dominantes&#46; Un peque&#241;o porcentaje de pacientes con c&#225;ncer de mama avanzado con RPc&#44; a&#250;n experimentan recidiva sist&#233;mica &#40;13-25&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">6&#44;10&#44;28</span></a>&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">El estado de los ganglios axilares posquimioterapia es otro factor pron&#243;stico importante&#44; varios estudios han evaluado que la QN reduce la incidencia de pN&#43;<a class="elsevierStyleCrossRefs" href="#bib0280"><span class="elsevierStyleSup">12&#44;29&#8211;34</span></a>&#44; y el pron&#243;stico es inversamente proporcional al n&#250;mero de pN&#43;<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">6&#44;12&#44;30&#44;31</span></a>&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">La ausencia de ganglios afectados puede reflejar la sensibilidad de los f&#225;rmacos&#44; al menos en algunos casos<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">12</span></a>&#46; Pocos estudios han evaluado la raz&#243;n ganglionar posquimioterapia y las pacientes con una mayor raz&#243;n ganglionar &#40;tambi&#233;n descrito como porcentaje de ganglios afectados&#41; ten&#237;an un pobre pron&#243;stico en la supervivencia&#46; Estos estudios evaluaron el porcentaje de ganglios afectados en comparaci&#243;n con el n&#250;mero absoluto de ganglios afectados&#44; se&#241;alando que este par&#225;metro puede ser superior como factor indicador independiente en pacientes con c&#225;ncer de mama en estadio II &#47;III<a class="elsevierStyleCrossRefs" href="#bib0395"><span class="elsevierStyleSup">35&#44;36</span></a>&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">Estudios moleculares han encontrado que las diferencias gen&#233;ticas observadas en las c&#233;lulas del tumor primario y de met&#225;stasis en los ganglios linf&#225;ticos axilares podr&#237;an explicar los diferentes resultados de quimiosensibilidad&#44; esto repercute en la SLE<a class="elsevierStyleCrossRefs" href="#bib0280"><span class="elsevierStyleSup">12&#44;30</span></a>&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">Para el grupo entero en este estudio&#44; el n&#250;mero de ganglios linf&#225;ticos axilares metast&#225;sicos residuales en el an&#225;lisis multivariado de Cox fue un predictor independiente de la SLE&#44; con una mediana de seguimiento de 45 meses el subgrupo de 4 pN&#43; o m&#225;s &#40;<span class="elsevierStyleItalic">p</span> &#61; 0&#46;003&#41; tuvo un impacto negativo en el pron&#243;stico&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">Hay informaci&#243;n suficiente del uso de las antraciclinas &#40;doxorrubicina&#44; epirrubicina&#41; como tratamiento de primera elecci&#243;n en la QN&#46; Al emplear un m&#237;nimo de 3 a 4 ciclos se obtiene una baja tasa de RPc &#40;3 al 16&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">6&#44;37&#8211;40</span></a>&#46; Los ciclos adicionales pueden ser considerados para maximizar la respuesta&#44; de modo que&#44; se han preferido 6 ciclos de antraciclinas como QN para obtener un mejor resultado en la tasa de RPc &#40;15 al 24&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0310"><span class="elsevierStyleSup">18&#44;28&#44;41&#44;42</span></a>&#46; Por lo tanto&#44; 6 ciclos son mejores que 4 ciclos de FEC&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">En este estudio el uso de un mayor n&#250;mero de ciclos de epirrubicina tuvo un ligero incremento no significativo &#40;<span class="elsevierStyleItalic">p</span> &#61; 0&#46;331&#41; en la SG&#46; Los ciclos adicionales parecen reflejar una mayor eficacia en comparaci&#243;n con un periodo de tratamiento m&#225;s corto<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">7&#44;18&#44;32&#8211;34&#44;43</span></a>&#46; Otro beneficio de la QN es la posibilidad de cambiar a un r&#233;gimen diferente si el tumor no responde<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">32&#8211;34&#44;43</span></a>&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">El an&#225;lisis de varios ensayos aleatorios han informado una probabilidad de obtener una mayor tasa de RPc para las mujeres con tumores RE negativos en comparaci&#243;n con tumores RE positivos independientemente del r&#233;gimen&#44; del f&#225;rmaco o duraci&#243;n de la QN<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">3&#44;6&#44;11&#44;29&#44;33&#44;37&#44;44</span></a>&#46; En contraste con los estudios anteriormente mencionados&#44; en este reporte los tumores RE positivos se correlacionaron favorablemente con una RPc&#46; En cambio&#44; la ausencia de expresi&#243;n de los RE mostraron un favorable incremento no significativo &#40;83&#37;&#59; <span class="elsevierStyleItalic">p &#61;</span> 0&#46;198&#41; en la SLE a 5 a&#241;os&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Aunque la muestra de este estudio no fue lo suficientemente grande&#44; se pudo agrupar un n&#250;mero determinado de pacientes de acuerdo a la etapa avanzada&#46; El estudio tiene ciertas limitaciones como&#58; el an&#225;lisis retrospectivo&#44; la probabilidad de sesgo de selecci&#243;n en pacientes con esquema completo de QN y la baja tasa de RPc&#44; este &#250;ltimo&#44; quiz&#225;s debido relativamente a tumores demasiadso grandes que podr&#237;an contribuir a debilitar el valor pron&#243;stico de la RPc&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">No obstante&#44; nuestros resultados pueden ser lo suficientemente consistentes dado que nuestra poblaci&#243;n es homog&#233;nea en t&#233;rminos del apego de un tratamiento homog&#233;neo con quimioterapia y cirug&#237;a&#46; La cirug&#237;a fue realizada por dos cirujanos onc&#243;logos y la quimioterapia fue aplicada por un onc&#243;logo m&#233;dico en una sola instituci&#243;n&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">A pesar de un n&#250;mero limitado de eventos en cada cohorte&#44; es posible sacar conclusiones definitivas de este estudio donde no se identific&#243; un beneficio significativo en t&#233;rminos de la SLE y SG para aquellas pacientes que ten&#237;an una RPc en comparaci&#243;n con aquellas que ten&#237;an un tumor residual invasivo&#46; Las pacientes del grupo con tumor residual con pN&#43; &#40;&#62;4&#41; posquimioterapia han sido capaces de tener una buena expectativa de vida en ambas cohortes&#44; una posible explicaci&#243;n es el sesgo de selecci&#243;n de pacientes con un n&#250;mero diferente de ciclos sin ser aleatorizados y al tama&#241;o limitado de la muestra&#46; Por lo tanto&#44; los datos deben ser interpretados con cautela&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Conclusi&#243;n</span><p id="par0240" class="elsevierStylePara elsevierViewall">La epirrubicina es un f&#225;rmaco quimioterap&#233;utico de primera elecci&#243;n en el tratamiento de pacientes con c&#225;ncer de mama avanzado&#46; Aunque este estudio proporcion&#243; informaci&#243;n limitada para indicar un mejor r&#233;gimen de quimioterapia para tratar el CMLA&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">La duraci&#243;n de la quimioterapia es importante&#44; en nuestro hospital&#44; 6 ciclos de epirrubicina neoadyuvante con dosis alta de epirrubicina tuvo un incremento ligero en la tasa de efectividad &#40;RPc&#41;&#44; sin embargo no hubo posibilidad de mejorar las tasas de SLE y de ganglios axilares negativos en comparaci&#243;n con un periodo de tratamiento m&#225;s corto&#46;</p><p id="par0250" class="elsevierStylePara elsevierViewall">Los resultados de una baja tasa de RPc en este estudio y el mal pron&#243;stico en las pacientes con CMLA justifican el desarrollo de nuevas estrategias con f&#225;rmacos citost&#225;ticos y esquemas diferentes para obtener mejores resultados&#46;</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Financiaci&#243;n</span><p id="par0255" class="elsevierStylePara elsevierViewall">Ninguna&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Conflicto de intereses</span><p id="par0260" class="elsevierStylePara elsevierViewall">Los autores declaran no tener ning&#250;n conflicto de intereses&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres683387"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Objetivo"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Pacientes y m&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusi&#243;n"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec688878"
          "titulo" => "Palabras clave"
        ]
        2 => array:3 [
          "identificador" => "xres683386"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Objective"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Patients and methods"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusion"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec688877"
          "titulo" => "Keywords"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Pacientes y m&#233;todos"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Selecci&#243;n de las pacientes"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Quimioterapia neoadyuvante"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Criterios de respuesta"
            ]
            3 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Seguimiento"
            ]
            4 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "M&#233;todo estad&#237;stico"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0040"
          "titulo" => "Resultados"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Respuesta cl&#237;nica"
            ]
            1 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Respuesta patol&#243;gica"
            ]
            2 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Predicci&#243;n de la RPc"
            ]
            3 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "An&#225;lisis univariado"
            ]
            4 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "An&#225;lisis multivariado"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Discusi&#243;n"
        ]
        8 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conclusi&#243;n"
        ]
        9 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Financiaci&#243;n"
        ]
        10 => array:2 [
          "identificador" => "sec0085"
          "titulo" => "Conflicto de intereses"
        ]
        11 => array:1 [
          "titulo" => "Referencias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2016-03-11"
    "fechaAceptado" => "2016-05-01"
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec688878"
          "palabras" => array:3 [
            0 => "Quimioterapia neoadyuvante"
            1 => "Respuesta patol&#243;gica completa"
            2 => "C&#225;ncer de mama avanzado"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec688877"
          "palabras" => array:3 [
            0 => "Neoadjuvant chemotherapy"
            1 => "Pathological complete response"
            2 => "Advanced breast cancer"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objetivo</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">El objetivo primario fue evaluar la respuesta patol&#243;gica completa &#40;RPc&#41; y del objetivo secundario&#44; la supervivencia de las pacientes con c&#225;ncer de mama avanzado tratadas con dosis alta de epirrubicina neoadyuvante y periodos diferentes&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Pacientes y m&#233;todos</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Las pacientes recibieron FE<span class="elsevierStyleInf">100</span>C &#40;5-fluorouracilo 500<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#44; epirrubicina 100<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#44; ciclofosfamida 600<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#41; ya sea de 4 o 6 ciclos&#46; El an&#225;lisis de regresi&#243;n log&#237;stica de la predicci&#243;n de la RPc se ajust&#243; con factores predictores&#46; Las curvas de Kaplan-Meier y riesgo proporcional de Cox fueron realizados&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Resultados</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Se incluyeron 60 pacientes por grupo&#46; Tras recibir 6 FE<span class="elsevierStyleInf">100</span>C se observ&#243; un incremento no significativo en la tasa de RPc &#40;16&#46;7&#37;&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;283&#41;&#46; El an&#225;lisis de regresi&#243;n log&#237;stica revel&#243; que solo la etapa cl&#237;nica IIIA &#40;OR&#44; 11&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;023&#41; fue factor predictivo de lograr una RPc&#46; El an&#225;lisis univariado revel&#243; una diferencia estad&#237;sticamente significativa a favor de tumores IIIA &#40;82&#37;&#59; <span class="elsevierStyleItalic">p</span>&#61; 0&#46;042&#41; y ganglios axilares negativos &#40;96&#37;&#59; <span class="elsevierStyleItalic">p</span>&#61; 0&#46;000&#41; en la supervivencia libre de enfermedad&#46; En el an&#225;lisis multivariado&#44; el grupo 4 ganglios positivos o m&#225;s &#40;raz&#243;n de riesgos &#91;HR&#93;&#44; 19&#46;6&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;003&#41; tuvo el peor pron&#243;stico&#46; El efecto del tratamiento no fue significativo para la RPc &#40;HR&#44; 3&#46;9&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;184&#41; y n&#250;mero de ciclos administrados &#40;HR&#44; 1&#46;3&#59; <span class="elsevierStyleItalic">p</span> &#61; 0&#46;412&#41; en la SLE&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusi&#243;n</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Los datos muestran un incremento ligero en la efectividad &#40;RPc&#41; con 6 FE<span class="elsevierStyleInf">100</span>C&#44; sin embargo no hubo posibilidad de mejorar las tasas de SLE y de ganglios negativos posquimioterapia comparado con un periodo de tratamiento m&#225;s corto&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Objetivo"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Pacientes y m&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusi&#243;n"
          ]
        ]
      ]
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objective</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">The primary endpoint was to assess the pathological complete response &#40;pCR&#41; rate&#44; and the secondary endpoint was to determine the survival of the patients with advanced breast cancer treated with high doses of neoadjuvant epirubicin&#44; and for different treatment periods&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Patients and methods</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">The patients received FE<span class="elsevierStyleInf">100</span>C &#40;5-fluorouracil 500<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#44; epirubicin 100<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#44; cyclophosphamide 600<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#41; in either 4 or 6 cycles&#46;</p><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A logistic regression analysis was performed to identify the relationship of pCR with predictive factors&#46; Kaplan-Meier plots and Cox proportional hazard were performed&#46; The groups were compared using log-rank test&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Results</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">The study included 60 patients per group&#46; A non-significant increase in the pCR rate &#40;16&#46;7&#37;&#59; <span class="elsevierStyleItalic">p</span>&#61;&#46;283&#41; was observed after receiving 6 FE<span class="elsevierStyleInf">100</span>C&#46; The logistic regression analysis revealed that only clinical stage IIIA &#40;OR&#44; 11&#59; <span class="elsevierStyleItalic">p</span>&#61;&#46;023&#41; was more likely to achieve a pCR&#46; The univariate analysis showed a statistically significant difference in favour of IIIA tumours &#40;82&#37;&#59; <span class="elsevierStyleItalic">p</span>&#61;&#46;042&#41;&#44; and negative axillary lymph nodes &#40;96&#37;&#59; <span class="elsevierStyleItalic">p</span>&#61;&#46;000&#41; in disease-free survival&#46; In the multivariate analysis&#44; the group with more than 4 positive lymph nodes &#40;hazard ratio &#91;HR&#93;&#44; 19&#46;6&#59; <span class="elsevierStyleItalic">p</span>&#61;&#46;003&#41; had the worst prognosis&#46; The treatment effect was not significant for the pCR &#40;HR&#44; 3&#46;9&#59; <span class="elsevierStyleItalic">p</span>&#61;&#46;184&#41;&#44; or the number of cycles given &#40;HR&#44; 1&#46;3&#59; <span class="elsevierStyleItalic">p</span> &#61; &#46;412&#41; on disease free survival&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusion</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">The results show a slight increase in the effectiveness &#40;pCR&#41; with 6 FE<span class="elsevierStyleInf">100</span>C&#44; however there was no chance of improving the disease-free survival and the post-chemotherapy negative lymph node rates compared with a shorter treatment period&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Objective"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Patients and methods"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusion"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Este trabajo se present&#243; dentro del marco del XXXIII Congreso Nacional de Oncolog&#237;a llevado a cabo del 21 al 24 de octubre de 2015 en Canc&#250;n&#44; Q&#46; Roo&#44; M&#233;xico&#46; &#40;Abstract<span class="elsevierStyleItalic">&#58;</span> folio 122&#41;&#46;</p>"
      ]
    ]
    "multimedia" => array:9 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2843
            "Ancho" => 1373
            "Tamanyo" => 173634
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Diferencias en las curvas Kaplan-Meier de acuerdo a la etapa cl&#237;nica de las pacientes con c&#225;ncer de mama avanzado&#46; Las pacientes con tumores EIIIA tuvieron una mejora significativa en la A&#41; supervivencia libre de enfermedad y B&#41; supervivencia global&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 2960
            "Ancho" => 1359
            "Tamanyo" => 196350
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Diferencias en las curvas Kaplan-Meier ajustado con 0&#44; 1 a 3 y 4 o m&#225;s ganglios positivos de las pacientes con c&#225;ncer de mama avanzado&#46; Las pacientes con 4 ganglios positivos o m&#225;s tuvieron el peor pron&#243;stico en la A&#41; supervivencia libre de enfermedad y B&#41; supervivencia global&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figura 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 3042
            "Ancho" => 1358
            "Tamanyo" => 204246
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Diferencias en las curvas Kaplan-Meier de acuerdo a la respuesta patol&#243;gica de las pacientes con cancer de mama avanzado&#46; Las pacientes con RPc tuvieron un ligero incremento no significativo en la A&#41; supervivencia libre de enfermedad y B&#41; supervivencia global&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">F&#58; 5-fluorouracilo&#59; E&#58; epirrubicina&#59; C&#58; ciclofosfamida&#59; &#199;&#58; 6&#46;<span class="elsevierStyleSup">a</span>&#46; edici&#243;n de la clasificaci&#243;n de TNM del AJCC&#59; &#43;SBR&#58; escala Scarff-Bloom-Richardson&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " rowspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Caracter&#237;stica</th><th class="td" title="table-head  " align="left" valign="top" scope="col">4 FE<span class="elsevierStyleInf">100</span>C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">6 FE<span class="elsevierStyleInf">100</span>C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> &#61; 60 &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> &#61; 60 &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Edad&#44; a&#241;os</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8804; 50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">32 &#40;53&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">23 &#40;38&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">0&#46;099</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#62; 50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">28 &#40;46&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">37 &#40;61&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Tama&#241;o del tumor</span> &#231;</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4 &#40;6&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">7 &#40;11&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">0&#46;381</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">38 &#40;63&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">31 &#40;51&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">18 &#40;30&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">22 &#40;36&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Estado ganglionar &#231;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">18 &#40;30&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">19 &#40;31&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">0&#46;835</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">40 &#40;66&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">40 &#40;66&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">2 &#40;3&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1 &#40;1&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Etapa cl&#237;nica &#231;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">40 &#40;66&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">36 &#40;60&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">0&#46;561</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">18 &#40;30&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">23 &#40;38&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">2 &#40;3&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1 &#40;1&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Grado histol&#243;gico &#43; SBR</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>BD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4 &#40;6&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4 &#40;6&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">0&#46;824</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>MD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">38 &#40;63&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">41 &#40;68&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>PD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">18 &#40;30&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15 &#40;25&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Tipo histol&#243;gico</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Ductal invasivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">38 &#40;63&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">40 &#40;66&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ref&#46;<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Lobular invasivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">18 &#40;30&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14 &#40;23&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;472&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Mixto invasivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4 &#40;6&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">6 &#40;10&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;603&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Invasi&#243;n linfovascular</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Ausente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">46 &#40;76&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">50 &#40;83&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">0&#46;361</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Presente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14 &#40;23&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">10 &#40;16&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Receptor de estr&#243;geno</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">17 &#40;28&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">23 &#40;38&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">0&#46;245</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">43 &#40;71&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">37 &#40;61&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Receptor progesterona</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">21 &#40;35&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">31 &#40;51&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">0&#46;065</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">39 &#40;65&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">29 &#40;48&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Estado del HER2</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">42 &#40;70&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">47 &#40;78&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">0&#46;409</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">18 &#40;30&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13 &#40;21&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Triple negativo</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">49 &#40;81&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">46 &#40;76&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">0&#46;500</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">11 &#40;18&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14 &#40;23&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1119648.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Un valor de <span class="elsevierStyleItalic">&#60; 0&#46;05</span> indica significaci&#243;n estad&#237;stica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas de las pacientes y del tumor</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">C&#58; ciclofosfamida&#59; E&#58; epirrubicina&#59; EEc&#58; enfermedad estable&#59; F&#58; 5-fluorouracilo&#59; RCc&#58; respuesta cl&#237;nica completa&#59; RCp&#58; respuesta cl&#237;nica parcial&#59; EE&#58; enfermedad estable&#59; RO&#58; respuesta objetica &#40;RCc &#43; RCp&#41;&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Tipo de respuesta&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">4 FE<span class="elsevierStyleInf">100</span>C</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">6 FE<span class="elsevierStyleInf">100</span>C</th><th class="td" title="table-head  " align="left" valign="top" scope="col"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">n &#61; 60 &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">RO&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">n &#61; 60 &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">RO&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="6" align="left" valign="top"><span class="elsevierStyleItalic">Respuesta cl&#237;nica</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>RCc&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">5 &#40;8&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="center" valign="middle">65&#46;0&#37;</td><td class="td" title="table-entry  " align="char" valign="top">20 &#40;33&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="center" valign="middle">85&#46;0&#37;</td><td class="td" title="table-entry  " rowspan="3" align="center" valign="middle">0&#46;011</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>RCp&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">34 &#40;56&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">31 &#40;51&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>EE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">21 &#40;35&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">9 &#40;15&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="6" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="6" align="left" valign="top"><span class="elsevierStyleItalic">Respuesta patol&#243;gica completa &#40;RPc&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">6 &#40;10&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">10 &#40;16&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="center" valign="middle">0&#46;283</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">54 &#40;90&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">50 &#40;83&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1119647.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Un valor de <span class="elsevierStyleItalic">&#60; 0&#46;05</span> indica significaci&#243;n estad&#237;stica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Tasa de la respuesta cl&#237;nica y respuesta patol&#243;gica posquimioterapia en pacientes con c&#225;ncer de mama avanzado</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="6" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">N&#250;mero de ganglios axilares involucrados posquimioterapia</th></tr><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">0<br>ganglios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">1-3<br>ganglios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">4-9<br>ganglios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">&#62;10<br>ganglios&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">N&#250;mero de ciclos&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4 ciclos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">20 &#40;33&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">19 &#40;31&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">17 &#40;28&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4 &#40;6&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="2" align="center" valign="middle">&#46;847</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">6 ciclos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">21 &#40;35&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">17 &#40;28&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">20 &#40;33&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">2 &#40;3&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1119646.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Un valor de <span class="elsevierStyleItalic">&#60; 0&#46;05</span> indica significaci&#243;n estad&#237;stica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Correlaci&#243;n entre el estado ganglionar axilar patol&#243;gico y n&#250;mero de ciclos</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">HER2&#58; receptor 2 del factor de crecimiento epid&#233;rmico humano&#59; IC&#58; intervalo de confianza&#59; OR&#58; odds ratio&#59; RE&#58; receptor de estr&#243;geno&#59; RPc&#58; respuesta patol&#243;gica completa&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Modelo de regresi&#243;n log&#237;stica&#58;</th><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Univariado</th><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Multivariado</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">OR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC 95&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">OR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC 95&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Etapa cl&#237;nica&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIB-C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIBA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">76&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">11&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;40 - 86&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;023&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">11&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;47 - 92&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;020&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Estado del RE&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">40&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;36 - 3&#46;46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;849&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;32 - 3&#46;54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;902&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Estado HER2&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">32&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">88&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;32 - 3&#46;71&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;871&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;31 - 4&#46;00&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;857&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">N&#250;mero ciclos&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>4 ciclos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>6 ciclos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;61 - 5&#46;31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;287&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">2&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;66 - 6&#46;24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;217&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1119645.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Un valor de <span class="elsevierStyleItalic">&#60; 0&#46;05</span> indica significaci&#243;n estad&#237;stica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Factores predictores para alcanzar una RPc de acuerdo con el an&#225;lisis de regresi&#243;n log&#237;stica&#44; &#40;<span class="elsevierStyleItalic">n</span> &#61; 120&#41;</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Tabla 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">RPc&#58; respuesta patol&#243;gica completa&#59; SG&#58; supervivencia global&#59; SLE&#58; supervivencia libre de enfermedad&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">SLE<br>5 a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">SG<br>5 a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Eventos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">&#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">muertes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">&#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Etapa cl&#237;nica</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">76&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">82&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;042&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;049&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIB-C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">58&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Ganglios axilares</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">97&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;000&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">96&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;000&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>1-3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">63&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#62; 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">57&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">RPc</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">93&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;071&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">92&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;061&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">104&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">71&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">68&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Receptor estr&#243;geno</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">40&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;198&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">82&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;222&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">70&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">68&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">N&#250;mero de ciclos</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Seis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">77&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;293&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">76&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;210&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Cuatro&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">71&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">69&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1119644.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Un valor de <span class="elsevierStyleItalic">&#60; 0&#46;05</span> indica significaci&#243;n estad&#237;stica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">An&#225;lisis univariado de la SLE y SG para factores predictores&#44; &#40;<span class="elsevierStyleItalic">n</span> &#61; 120&#41;</p>"
        ]
      ]
      8 => array:8 [
        "identificador" => "tbl0030"
        "etiqueta" => "Tabla 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at6"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">HR&#58; raz&#243;n de riesgos&#59; IC&#58; intervalo de confianza&#59; RE&#58; receptor de estr&#243;geno&#59; RPc&#58; respuesta patol&#243;gica completa&#59; SG&#58; supervivencia global&#59; SLE&#58; supervivencia libre de enfermedad&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">SLE</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">SG</th><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC 95&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC 95&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Ganglios&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>1-3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">19&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">2&#46;5-149&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;003&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">19&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">2&#46;5-147&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;004&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#62; 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">12&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;5-97&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;017&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">12&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;7-95&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;016&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Etapa cl&#237;nica&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span> IIIA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">76&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IIIB-C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;8-3&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;126&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;8-3&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;149&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">Estado del RE&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">40&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;2-1&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;219&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;2-1&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;259&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">RPc&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">104&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">3&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;5-30&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;184&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;5-31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;170&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">N&#250;m&#46; de ciclos&#58;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>6 FEC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>4 FEC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;6-2&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;412&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;6-3&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;331&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1119649.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0030"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Un valor de <span class="elsevierStyleItalic">&#60; 0&#46;05</span> indica significaci&#243;n estad&#237;stica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">An&#225;lisis multivariado de acuerdo con el modelo de Cox&#44; &#40;<span class="elsevierStyleItalic">n</span> &#61; 120&#41;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Referencias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:44 [
            0 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of stage III primary breast cancer with primary chemotherapy&#44; surgery and radiation therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "G&#46;N&#46; Hortobagyi"
                            1 => "F&#46;C&#46; Ames"
                            2 => "A&#46;U&#46; Buzdar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer&#46;"
                        "fecha" => "1988"
                        "volumen" => "62"
                        "paginaInicial" => "2507"
                        "paginaFinal" => "2516"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3056604"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical practice guidelines for the care and treatment of breast cancer&#58; 15&#46; Treatment for women with stage III or locally advanced breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "T&#46; Shenkier"
                            1 => "L&#46; Weir"
                            2 => "M&#46; Levine"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "CMAJ&#46;"
                        "fecha" => "2004"
                        "volumen" => "170"
                        "paginaInicial" => "983"
                        "paginaFinal" => "994"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15023926"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary systemic therapy of breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "I&#46; Sachelarie"
                            1 => "M&#46;L&#46; Grossbard"
                            2 => "M&#46; Chadha"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1634/theoncologist.11-6-574"
                      "Revista" => array:6 [
                        "tituloSerie" => "The Oncologist&#46;"
                        "fecha" => "2006"
                        "volumen" => "11"
                        "paginaInicial" => "574"
                        "paginaFinal" => "589"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16794237"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Results of the neoadjuvant chemotherapy&#44; and external and radiation therapy in breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "C&#46; Jacquillat"
                            1 => "M&#46; Weil"
                            2 => "F&#46; Baillet"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer&#46;"
                        "fecha" => "1990"
                        "volumen" => "66"
                        "paginaInicial" => "119"
                        "paginaFinal" => "129"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2112976"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer&#58; findings from National Surgical Adjuvant Breast Project B-18"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "B&#46; Fisher"
                            1 => "A&#46;M&#46; Brown"
                            2 => "E&#46; Mamounas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1997.15.7.2483"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "1997"
                        "volumen" => "15"
                        "paginaInicial" => "2483"
                        "paginaFinal" => "2493"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9215816"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "H&#46;M&#46; Kuerer"
                            1 => "L&#46;A&#46; Newman"
                            2 => "T&#46;L&#46; Smith"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1999.17.2.460"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "1999"
                        "volumen" => "17"
                        "paginaInicial" => "460"
                        "paginaFinal" => "469"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10080586"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognostic role of clinical&#44; pathological and biological characteristics in patients with locally advanced breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46;H&#46; Honkoop"
                            1 => "P&#46;J&#46; van Diest"
                            2 => "J&#46;S&#46; de Jong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Cancer&#46;"
                        "fecha" => "1998"
                        "volumen" => "77"
                        "paginaInicial" => "621"
                        "paginaFinal" => "626"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9484820"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46; Wang"
                            1 => "T&#46;A&#46; Buchholz"
                            2 => "L&#46;P&#46; Middleton"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.10585"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer&#46;"
                        "fecha" => "2002"
                        "volumen" => "94"
                        "paginaInicial" => "3107"
                        "paginaFinal" => "3114"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12115341"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Locally advanced&#47;inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy&#58; are there molecular markers in the primary tumour that predict for 5-year clinical outcome&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "H&#46; Bonnefoi"
                            1 => "S&#46; Diebold-Berger"
                            2 => "P&#46; Therasse"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Oncol&#46;"
                        "fecha" => "2003"
                        "volumen" => "14"
                        "paginaInicial" => "406"
                        "paginaFinal" => "413"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12598346"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46;M&#46; Gonzalez-Angulo"
                            1 => "S&#46;E&#46; McGuire"
                            2 => "T&#46;A&#46; Buchholz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2005.11.124"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2005"
                        "volumen" => "23"
                        "paginaInicial" => "7098"
                        "paginaFinal" => "7104"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16192593"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary chemotherapy in operable breast cancer&#58; eight-year experience at the Milan Cancer Institute"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "G&#46; Bonadonna"
                            1 => "P&#46; Valagussa"
                            2 => "C&#46; Brambilla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1998.16.1.93"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "1998"
                        "volumen" => "16"
                        "paginaInicial" => "93"
                        "paginaFinal" => "100"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9440728"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46;Y&#46; Pierga"
                            1 => "E&#46; Mouret"
                            2 => "V&#46; Dieras"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1054/bjoc.2000.1461"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Cancer&#46;"
                        "fecha" => "2000"
                        "volumen" => "83"
                        "paginaInicial" => "1480"
                        "paginaFinal" => "1487"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11076657"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "D&#46; Kandioler-Eckersberger"
                            1 => "C&#46; Ludwig"
                            2 => "M&#46; Rudas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cancer Res&#46;"
                        "fecha" => "2000"
                        "volumen" => "6"
                        "paginaInicial" => "50"
                        "paginaFinal" => "56"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10656431"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46; Gerdes"
                            1 => "H&#46; Lemke"
                            2 => "H&#46; Baisch"
                            3 => "H&#46; Walker"
                            4 => "U&#46; Schwab"
                            5 => "H&#46; Stein"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Immunol&#46;"
                        "fecha" => "1984"
                        "volumen" => "133"
                        "paginaInicial" => "1710"
                        "paginaFinal" => "1715"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/6206131"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ki-67 expression in breast carcinoma&#58; its association with grading systems&#44; clinical parameters&#44; and other prognostic factors&#8211;a surrogate marker&#63;"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "International Breast Cancer Study Group"
                          "etal" => true
                          "autores" => array:3 [
                            0 => "H&#46; Trihia"
                            1 => "S&#46; Murray"
                            2 => "K&#46; Price"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.11188"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer&#46;"
                        "fecha" => "2003"
                        "volumen" => "97"
                        "paginaInicial" => "1321"
                        "paginaFinal" => "1331"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12599241"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46; Makris"
                            1 => "T&#46;J&#46; Powles"
                            2 => "M&#46; Dowsett"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cancer Res&#46;"
                        "fecha" => "1997"
                        "volumen" => "3"
                        "paginaInicial" => "593"
                        "paginaFinal" => "600"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9815725"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide &#40;FEC&#41; chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "E&#46; Van der Wall"
                            1 => "E&#46;J&#46;T&#46; Rutgers"
                            2 => "M&#46;J&#46; Holtkampl"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Cancer&#46;"
                        "fecha" => "1996"
                        "volumen" => "73"
                        "paginaInicial" => "1080"
                        "paginaFinal" => "1085"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8624267"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Neoadjuvant FEC100 for operable breast cancer&#58; eight-year experience at Centre Jean Perrin"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46;A&#46; Mouret-Reyner"
                            1 => "C&#46;J&#46; Abrial"
                            2 => "J&#46;P&#46; Ferriere"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Breast Cancer&#46;"
                        "fecha" => "2004"
                        "volumen" => "5"
                        "paginaInicial" => "303"
                        "paginaFinal" => "307"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15507178"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Final results of a randomized phase III trial comparing cyclophosphamide&#44; epirubicin and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer&#58; an EORT-NCIC-SAKK multicenter study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "P&#46; Therasse"
                            1 => "L&#46; Mauriac"
                            2 => "M&#46; Welnicka-Jaskiewicz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2003.05.135"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2003"
                        "volumen" => "21"
                        "paginaInicial" => "843"
                        "paginaFinal" => "850"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12610183"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Revision of the American Joint Committee on Cancer staging system for breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46;E&#46; Singletary"
                            1 => "C&#46; Alfred"
                            2 => "P&#46; Ashley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2002.02.026"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2002"
                        "volumen" => "20"
                        "paginaInicial" => "3628"
                        "paginaFinal" => "3636"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12202663"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An&#225;lisis de la efectividad de epirrubicina neoadyuvante de alta dosis al usar 4 vs&#46; 6 ciclos en pacientes con c&#225;ncer de mama localmente avanzado"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "N&#46; Ram&#237;rez-Torres"
                            1 => "A&#46; P&#233;rez-Puentes"
                            2 => "H&#46; Astudillo-de la Vega"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Mex Mastol&#46;"
                        "fecha" => "2014"
                        "volumen" => "4"
                        "paginaInicial" => "91"
                        "paginaFinal" => "99"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reporting results of cancer treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46;B&#46; Miller"
                            1 => "B&#46; Hoogstraten"
                            2 => "Staquet"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer&#46;"
                        "fecha" => "1981"
                        "volumen" => "47"
                        "paginaInicial" => "207"
                        "paginaFinal" => "214"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7459811"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inflammatory breast cancer&#46; Pilot study of intensive induction chemotherapy &#40;FEC-HD&#41; results in a high histologic response rate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "B&#46; Chevallier"
                            1 => "H&#46; Roche"
                            2 => "J&#46;P&#46; Olivier"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Oncol&#46;"
                        "fecha" => "1993"
                        "volumen" => "16"
                        "paginaInicial" => "223"
                        "paginaFinal" => "228"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8338056"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nonparametric estimation from incomplete observations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "E&#46;L&#46; Kaplan"
                            1 => "P&#46; Meier"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Stat Assoc&#46;"
                        "fecha" => "1958"
                        "volumen" => "53"
                        "paginaInicial" => "457"
                        "paginaFinal" => "481"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Regression models and life tables &#40;with discussion&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "D&#46;R&#46; Cox"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Stat Soc B&#46;"
                        "fecha" => "1972"
                        "volumen" => "34"
                        "paginaInicial" => "187"
                        "paginaFinal" => "220"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Overview of resistance to systemic therapy in patients with breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46;M&#46; Gonzalez-Angulo"
                            1 => "F&#46; Morales-Vasquez"
                            2 => "G&#46;N&#46; Hortobagyi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Adv Exp Med Biol&#46;"
                        "fecha" => "2007"
                        "volumen" => "608"
                        "paginaInicial" => "1"
                        "paginaFinal" => "22"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17993229"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of preoperative chemotherapy on the outcome of women with operable breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "B&#46; Fisher"
                            1 => "J&#46; Bryant"
                            2 => "N&#46; Wolmark"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1998.16.8.2672"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "1998"
                        "volumen" => "16"
                        "paginaInicial" => "2672"
                        "paginaFinal" => "2685"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9704717"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "P&#46; Chollet"
                            1 => "S&#46; Amat"
                            2 => "H&#46; Cure"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/sj.bjc.6600210"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Cancer&#46;"
                        "fecha" => "2002"
                        "volumen" => "86"
                        "paginaInicial" => "1041"
                        "paginaFinal" => "1046"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11953845"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oestrogen receptor status&#44; pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46;E&#46; Ring"
                            1 => "I&#46;E&#46; Smith"
                            2 => "S&#46; Ashley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/sj.bjc.6602235"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Cancer&#46;"
                        "fecha" => "2004"
                        "volumen" => "91"
                        "paginaInicial" => "2012"
                        "paginaFinal" => "2017"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15558072"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "H&#46;M&#46; Kuerer"
                            1 => "L&#46;A&#46; Newman"
                            2 => "A&#46;U&#46; Buzdar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Surg&#46;"
                        "fecha" => "1988"
                        "volumen" => "176"
                        "paginaInicial" => "502"
                        "paginaFinal" => "509"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9926779"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "D&#46;R&#46; McCready"
                            1 => "G&#46;N&#46; Hortobagyi"
                            2 => "S&#46;W&#46; Kau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Surg&#46;"
                        "fecha" => "1989"
                        "volumen" => "124"
                        "paginaInicial" => "21"
                        "paginaFinal" => "25"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2910244"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Neoadjuvant chemotherapy in breast cancer&#58; Significantly enhanced response with docetaxel"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "I&#46;C&#46; Smith"
                            1 => "S&#46;D&#46; Heys"
                            2 => "A&#46;W&#46; Hutcheon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.2002.20.6.1456"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2002"
                        "volumen" => "20"
                        "paginaInicial" => "1456"
                        "paginaFinal" => "1466"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11896092"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide&#58; Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "H&#46;D&#46; Bear"
                            1 => "S&#46; Anderson"
                            2 => "A&#46; Brown"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2003.12.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2003"
                        "volumen" => "21"
                        "paginaInicial" => "4165"
                        "paginaFinal" => "4174"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14559892"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer&#58; the GEPARDUO study of the German Breast Group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "G&#46; Von Minckwitz"
                            1 => "G&#46; Raab"
                            2 => "A&#46; Caputo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2005.05.078"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2005"
                        "volumen" => "23"
                        "paginaInicial" => "2676"
                        "paginaFinal" => "2685"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15837982"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognostic impact of clinicopathologic parameters in stage II&#47;III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy&#58; paradoxical features of the triple negative breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "B&#46; Keam"
                            1 => "S&#46;A&#46; Im"
                            2 => "H&#46;J&#46; Kim"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-2407-7-203"
                      "Revista" => array:6 [
                        "tituloSerie" => "BMC Cancer&#46;"
                        "fecha" => "2007"
                        "volumen" => "7"
                        "paginaInicial" => "203"
                        "paginaFinal" => "213"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17976237"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognostic value of nodal ratios in node-positive breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "W&#46;A&#46; Woodward"
                            1 => "V&#46; Vinh-Hung"
                            2 => "N&#46;T&#46; Ueno"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2005.03.1526"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2006"
                        "volumen" => "24"
                        "paginaInicial" => "2910"
                        "paginaFinal" => "2916"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16782931"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0405"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil&#44; doxorubicin&#44; and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46;U&#46; Buzdar"
                            1 => "S&#46;E&#46; Singletary"
                            2 => "R&#46;L&#46; Theriault"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1999.17.11.3412"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "1999"
                        "volumen" => "17"
                        "paginaInicial" => "3412"
                        "paginaFinal" => "3417"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10550135"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0410"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Preoperative chemotherapy in primary operable breast cancer&#58; results from the European Organization for Research and Treatment on Cancer trial 10902"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46;A&#46; Van der Hage"
                            1 => "C&#46;J&#46; van de Velde"
                            2 => "J&#46;P&#46; Julien"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.2001.19.22.4224"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2001"
                        "volumen" => "19"
                        "paginaInicial" => "4224"
                        "paginaFinal" => "4237"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11709566"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0415"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relation of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "C&#46; Gajdos"
                            1 => "P&#46;I&#46; Tarter"
                            2 => "A&#46; Estabrook"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/jso.10090"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Surg Oncol&#46;"
                        "fecha" => "2002"
                        "volumen" => "80"
                        "paginaInicial" => "4"
                        "paginaFinal" => "11"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11967899"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0420"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant therapy in patients with breast cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "V&#46; Dieras"
                            1 => "P&#46; Fumoleau"
                            2 => "G&#46; Romieu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2004.02.122"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2004"
                        "volumen" => "22"
                        "paginaInicial" => "4958"
                        "paginaFinal" => "4965"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15611510"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0425"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "R&#46;L&#46; Jones"
                            1 => "S&#46;R&#46; Lakhani"
                            2 => "A&#46;E&#46; Ring"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/sj.bjc.6602950"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Cancer&#46;"
                        "fecha" => "2006"
                        "volumen" => "94"
                        "paginaInicial" => "358"
                        "paginaFinal" => "362"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16421590"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0430"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "6 cycles of FEC vs&#46;6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients&#58; preliminary results of a randomized phase II trial of Girec S01&#46; &#40;abstract&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "E&#46; Luporsi"
                            1 => "L&#46; Vanlemmens"
                            2 => "B&#46; Coudert"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Proc Am Soc Clin Oncol&#46;"
                        "fecha" => "2000"
                        "volumen" => "19"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0435"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "International expert panel on the use of primary &#40;preoperative&#41; systemic treatment of operable breast cancer&#58; review and recommendations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46; Kaufmann"
                            1 => "G&#46; von Minckwitz"
                            2 => "R&#46; Smith"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2003.01.136"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol&#46;"
                        "fecha" => "2003"
                        "volumen" => "21"
                        "paginaInicial" => "2600"
                        "paginaFinal" => "2608"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12829681"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0440"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46; Colleoni"
                            1 => "I&#46; Minchella"
                            2 => "G&#46; Mazzarol"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Oncol&#46;"
                        "fecha" => "2000"
                        "volumen" => "11"
                        "paginaInicial" => "1057"
                        "paginaFinal" => "1059"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11038046"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/16659201/0000001500000003/v1_201607090026/S1665920116300281/v1_201607090026/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "41757"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Art&#237;culos originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/16659201/0000001500000003/v1_201607090026/S1665920116300281/v1_201607090026/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665920116300281?idApp=UINPBA00004N"
]
Información del artículo
ISSN: 16659201
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 6 0 6
2024 Octubre 99 0 99
2024 Septiembre 54 5 59
2024 Agosto 66 2 68
2024 Julio 79 4 83
2024 Junio 53 8 61
2024 Mayo 55 3 58
2024 Abril 51 5 56
2024 Marzo 63 10 73
2024 Febrero 66 10 76
2024 Enero 78 4 82
2023 Diciembre 55 13 68
2023 Noviembre 74 7 81
2023 Octubre 133 11 144
2023 Septiembre 75 2 77
2023 Agosto 85 7 92
2023 Julio 103 4 107
2023 Junio 90 2 92
2023 Mayo 121 8 129
2023 Abril 91 5 96
2023 Marzo 111 2 113
2023 Febrero 125 16 141
2023 Enero 115 2 117
2022 Diciembre 62 6 68
2022 Noviembre 85 7 92
2022 Octubre 57 9 66
2022 Septiembre 60 34 94
2022 Agosto 83 5 88
2022 Julio 54 6 60
2022 Junio 62 7 69
2022 Mayo 81 13 94
2022 Abril 94 8 102
2022 Marzo 193 7 200
2022 Febrero 150 3 153
2022 Enero 118 4 122
2021 Diciembre 80 12 92
2021 Noviembre 136 13 149
2021 Octubre 93 10 103
2021 Septiembre 82 8 90
2021 Agosto 53 8 61
2021 Julio 76 7 83
2021 Junio 59 9 68
2021 Mayo 75 8 83
2021 Abril 137 14 151
2021 Marzo 91 4 95
2021 Febrero 44 7 51
2021 Enero 53 14 67
2020 Diciembre 64 12 76
2020 Noviembre 69 10 79
2020 Octubre 48 2 50
2020 Septiembre 48 10 58
2020 Agosto 43 6 49
2020 Julio 56 21 77
2020 Junio 69 6 75
2020 Mayo 87 7 94
2020 Abril 69 5 74
2020 Marzo 76 8 84
2020 Febrero 74 10 84
2020 Enero 68 5 73
2019 Diciembre 57 23 80
2019 Noviembre 74 7 81
2019 Octubre 57 8 65
2019 Septiembre 54 7 61
2019 Agosto 55 7 62
2019 Julio 70 8 78
2019 Junio 96 15 111
2019 Mayo 159 6 165
2019 Abril 98 5 103
2019 Marzo 14 6 20
2019 Febrero 15 1 16
2019 Enero 13 7 20
2018 Diciembre 7 4 11
2018 Noviembre 23 7 30
2018 Octubre 28 16 44
2018 Septiembre 22 3 25
2018 Agosto 19 13 32
2018 Julio 13 10 23
2018 Junio 14 4 18
2018 Mayo 9 10 19
2018 Abril 13 1 14
2018 Marzo 16 5 21
2018 Febrero 10 1 11
2018 Enero 15 5 20
2017 Diciembre 16 3 19
2017 Noviembre 9 2 11
2017 Octubre 12 4 16
2017 Septiembre 10 3 13
2017 Agosto 7 4 11
2017 Julio 17 2 19
2017 Junio 21 4 25
2017 Mayo 18 5 23
2017 Abril 12 3 15
2017 Marzo 19 28 47
2017 Febrero 20 3 23
2017 Enero 16 2 18
2016 Diciembre 21 1 22
2016 Noviembre 32 12 44
2016 Octubre 46 12 58
2016 Septiembre 42 19 61
2016 Agosto 42 10 52
2016 Julio 24 3 27
Mostrar todo

Siga este enlace para acceder al texto completo del artículo